WHO Centre for Patient Safety Seeks Comments on Proposed Patient Safety Solutions

The World Health Organization (WHO) Collaborating Centre for Patient Safety and the WHO World Alliance for Patient Safety, housed in Oakbrook Terrace and Oak Brook, Ill, have invited health ministries, health care provider organizations, health care professionals, patient safety advocates, consumers, and other interested parties to comment on five proposed, potentially lifesaving Patient Safety Solutions selected as priorities by the Collaborating Centres international steering committee.

PVT Plans to Install Equipment at BioReference Labs

PVT GmbH, Germany, a developer of diagnostic laboratory systems, and BioReference Laboratories Inc, Elmwood Park, NJ, an independent regional clinical lab, plan to install PVT’s RSA Pro system at BioReferences facility.

Nanogen’s CFO Announces Retirement

Nanogen Inc, San Diego, a developer of advanced diagnostic products, reports that Robert Saltmarsh, vice president and CFO, will retire at the end of Feb 2008.

Ventana Notified of Roche’s Intention to Seek Election of Directors

Ventana Medical Systems Inc, Tucson, Ariz, which specializes in tissue-based cancer diagnostics, has received notification from Roche, Switzerland, of its intention to seek the election of directors to the board of directors of Ventana at the company’s annual meeting of stockholders in June 2008.

Nanogen Seeks Special Meeting of Stockholders

Nanogen Inc, San Diego, a developer of advanced diagnostic products, has filed a preliminary proxy statement with the Securities and Exchange Commission for a special meeting of its stockholders.

Bio-Rad Issues Protein Enrichment Kit Application Note

Bio-Rad Laboratories Inc, Hercules, Calif, a multinational manufacturer and distributor of life science research and clinical diagnostic products, is offering a product application note detailing how its ProteoMiner protein enrichment kits concentrate and enrich low- and medium-abundance proteins for biomarker discovery.

Study Slated to Determine When CLL Patients Should Begin Treatment

Genzyme Genetics, Cambridge, Mass, a nationwide provider of genetic testing and counseling services for physicians and patients, plans to participate in a multi-center Cancer and Leukemia Group B study that will include 1,700 newly diagnosed patients with chronic lymphocytic leukemia.